drugset
drugset / Trial / NCT03721016

MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)

NCT03721016 ↗

Phase 3 Completed 415 enrolled Medy-Tox
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the safety and efficacy of MT10109L for the treatment of glabellar lines (GL) with or without concurrent treatment of lateral canthal lines (LCL) in participants with moderate to severe GL and LCL.

Timeline

Start
2018-10-26
Primary completion
2020-03-05
Completion
2021-01-22

Drugs

EvaluationDrugModalityDoseRoute
Subject NivobotulinumtoxinA Protein / enzyme biologic — Other

Indications

No indication recorded.